165 related articles for article (PubMed ID: 12089228)
1. Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent.
Osman I; Sherman E; Singh B; Venkatraman E; Zelefsky M; Bosl G; Scher H; Shah J; Shaha A; Kraus D; Cordon-Cardo C; Pfister DG
J Clin Oncol; 2002 Jul; 20(13):2980-7. PubMed ID: 12089228
[TBL] [Abstract][Full Text] [Related]
2. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
[TBL] [Abstract][Full Text] [Related]
3. P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy.
Lavertu P; Adelstein DJ; Myles J; Secic M
Laryngoscope; 2001 Nov; 111(11 Pt 1):1878-92. PubMed ID: 11801963
[TBL] [Abstract][Full Text] [Related]
4. Nuclear and cytoplasmic p53 expression in pharyngeal squamous cell carcinoma: prognostic implications.
Pukkila MJ; Kumpulainen EJ; Virtaniemi JA; Johansson RT; Halonen PM; Kellokoski JK; Kosunen AS; Nuutinen J; Kosma VM
Head Neck; 2002 Aug; 24(8):784-91. PubMed ID: 12203805
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of p27Kip1 expression in Basaloid Squamous Cell Carcinoma of the larynx.
Salerno G; Di Vizio D; Staibano S; Mottola G; Quaremba G; Mascolo M; Galli V; De Rosa G; Insabato L
BMC Cancer; 2006 Jun; 6():146. PubMed ID: 16740156
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression.
Osman I; Drobnjak M; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 Aug; 5(8):2082-8. PubMed ID: 10473090
[TBL] [Abstract][Full Text] [Related]
7. Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients.
Goan YG; Hsu HK; Chang HC; Chou YP; Chiang KH; Cheng JT
Ann Thorac Surg; 2005 Sep; 80(3):1007-16. PubMed ID: 16122475
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle proteins in laryngeal cancer: role in proliferation and prognosis.
Peschos D; Stefanou D; Vougiouklakis T; Assimakopoulos DA; Agnantis NJ
J Exp Clin Cancer Res; 2005 Sep; 24(3):431-7. PubMed ID: 16270530
[TBL] [Abstract][Full Text] [Related]
9. p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma.
Hirvikoski P; Kumpulainen E; Virtaniemi J; Johansson R; Haapasalo H; Marin S; Halonen P; Helin H; Raitiola H; Pukander J; Kellokumpu-Lehtinen P; Kosma VM
J Clin Oncol; 1997 Sep; 15(9):3111-20. PubMed ID: 9294474
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 and cyclin A1 protein expression in primary laryngeal squamous cell carcinomas do not correlate to second primary tumours of the head and neck.
Farhadieh RD; Smee R; Rees CG; Salardini A; Eggleton S; Yang JL; Russell PJ
ANZ J Surg; 2009; 79(1-2):48-54. PubMed ID: 19183379
[TBL] [Abstract][Full Text] [Related]
11. p14ARF protein expression is a predictor of both relapse and survival in squamous cell carcinoma of the anterior tongue.
Kwong RA; Kalish LH; Nguyen TV; Kench JG; Bova RJ; Cole IE; Musgrove EA; Sutherland RL
Clin Cancer Res; 2005 Jun; 11(11):4107-16. PubMed ID: 15930346
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients.
Nathan CO; Amirghahri N; Rice C; Abreo FW; Shi R; Stucker FJ
Laryngoscope; 2002 Dec; 112(12):2129-40. PubMed ID: 12461330
[TBL] [Abstract][Full Text] [Related]
13. The relation between hypoxia-inducible factor (HIF)-1alpha expression with p53 expression and outcome in surgically treated supraglottic laryngeal cancer.
Cabanillas R; Rodrigo JP; Secades P; Astudillo A; Nieto CS; Chiara MD
J Surg Oncol; 2009 May; 99(6):373-8. PubMed ID: 19226532
[TBL] [Abstract][Full Text] [Related]
14. Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients.
Schrader CH; Kolb M; Zaoui K; Flechtenmacher C; Grabe N; Weber KJ; Hielscher T; Plinkert PK; Hess J
Mol Cancer; 2015 May; 14():107. PubMed ID: 25990935
[TBL] [Abstract][Full Text] [Related]
15. Loss of MTBP expression is associated with reduced survival in a biomarker-defined subset of patients with squamous cell carcinoma of the head and neck.
Vlatković N; El-Fert A; Devling T; Ray-Sinha A; Gore DM; Rubbi CP; Dodson A; Jones AS; Helliwell TR; Jones TM; Boyd MT
Cancer; 2011 Jul; 117(13):2939-50. PubMed ID: 21692053
[TBL] [Abstract][Full Text] [Related]
16. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of microvessel density and p53 expression on the locoregional metastasis and survival of the patients with head and neck squamous cell carcinoma.
de Oliveira MV; Pereira Gomes EP; Pereira CS; de Souza LR; Barros LO; Mendes DC; Guimarães AL; De Paula AM
Appl Immunohistochem Mol Morphol; 2013 Oct; 21(5):444-51. PubMed ID: 23343952
[TBL] [Abstract][Full Text] [Related]
18. p53, p21 and p27 protein expression in head and neck cancer and their prognostic value.
Kapranos N; Stathopoulos GP; Manolopoulos L; Kokka E; Papadimitriou C; Bibas A; Yiotakis J; Adamopoulos G
Anticancer Res; 2001; 21(1B):521-8. PubMed ID: 11299798
[TBL] [Abstract][Full Text] [Related]
19. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma.
Bradford CR; Wolf GT; Carey TE; Zhu S; Beals TF; Truelson JM; McClatchey KD; Fisher SG
Otolaryngol Head Neck Surg; 1999 Nov; 121(5):534-8. PubMed ID: 10547465
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
